Clinical Trials on Non-Muscle Invasive Bladder Urothelial Carcinoma

Total 670 results

Fox Chase Cancer Center
Janssen Pharmaceuticals

Not yet recruiting

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE) (INSITE)

Urothelial Carcinoma | Non-Muscle Invasive Bladder Urothelial Carcinoma | Muscle Invasive Bladder Urothelial Carcinoma

United States
University of Roma La Sapienza

Not yet recruiting

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) (CUT-less)

Non-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)

Not yet recruiting

Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
IRCCS San Raffaele

Recruiting

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Bladder Cancer | Bladder Disease | Bladder Cancer Recurrent | Bladder Urothelial Carcinoma | Non Muscle Invasive Bladder Cancer | Bladder Neoplasm | Non-Muscle Invasive Bladder Urothelial Carcinoma | Non-Muscle Invasive Bladder Neoplasms | Bladder Cancer Stage I, With Cancer in Situ | Bladder Urothelial... and other conditions

Italy
Clinique Beau Soleil
Cepheid; Team Languedoc Mutualité / Nouvelles technologies

Completed

Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test. (Xpert Bladder)

Non-Invasive Bladder Urothelial Carcinoma | Non-Invasive Bladder Papillary Urothelial Carcinoma, Low Grade | Non-Invasive Bladder Papillary Urothelial Carcinoma, High Grade

France
Nucleix Ltd.

Completed

Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

Non Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial Carcinoma | Stage 0 Bladder Urothelial Carcinoma

United States
AstraZeneca
Hospital Israelita Albert Einstein

Recruiting

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER

Urothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder Cancer

Brazil
Tyra Biosciences, Inc

Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301)

Solid Tumor | Bladder Cancer | Advanced Solid Tumor | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | FGFR3 Gene Mutation | Urinary Tract Cancer | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Non-muscle-invasive Bladder Cancer | FGFR3 Gene Alteration | Urinary... and other conditions

Australia, United States, France, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
Incyte Corporation

Recruiting

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Bladder Cancer | NMIBC | Urothelial Carcinoma Recurrent | Non-Muscle Invasive Bladder Cancer

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage I Bladder Urothelial Carcinoma AJCC v6 and v7

United States, Canada
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
CG Oncology, Inc.

Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder Cancer

United States
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
UroGen Pharma Ltd.

Completed

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Superficial Bladder Urothelial Carcinoma

United States
Ain Shams University

Completed

Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer

Urinary Bladder Cancer | BCG | Urinary Bladder Neoplasm | Non-Muscle Invasive Bladder Urothelial Carcinoma | Trans Urethral Resection of a Bladder Tumor

Egypt
Aura Biosciences

Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
Yung NA
Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern Hospital

Recruiting

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial

Muscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial Carcinoma

Hong Kong
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma

United States
Tata Memorial Centre

Not yet recruiting

Intravesical BCG: is the Urinary Bladder Ready to Receive it

Non-Invasive Bladder Urothelial Carcinoma
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Invasive Bladder Mixed Carcinoma

United States, Guam, Puerto Rico
Henan Cancer Hospital

Recruiting

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Intraoperative Complications | Perfusion; Complications | High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Brigham and Women's Hospital

Not yet recruiting

Drug Screening Using IMD in Bladder Cancer

Muscle Invasive Bladder Urothelial Carcinoma

United States
enGene, Inc.

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Superficial Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

United States
Tianjin Medical University Second Hospital

Recruiting

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study

High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Tianjin Medical University Second Hospital

Recruiting

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Non-Muscle Invasive Bladder Urothelial Carcinoma | High-Risk

China
University of Virginia
American Cancer Society, Inc.; Integrated Translational Health Research Institute...

Recruiting

Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) (PRIMER)

Bladder Cancer | Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
Varian, a Siemens Healthineers Company
Washington University School of Medicine

Recruiting

Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer (ARTIA-Bladder)

Muscle Invasive Bladder Urothelial Carcinoma

United States
Pharmalink

Active, not recruiting

External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group (EVALUATION)

Non-muscle-invasive Bladder Cancer

Spain
Tianjin Medical University Second Hospital

Recruiting

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Huazhong University of Science and Technology

Recruiting

The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients

Bladder Cancer | Non-Muscle-Invasive Bladder Cancer

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC

Non-Muscle-Invasive Bladder Cancer (NMIBC)

China
RenJi Hospital
BeiGene; RemeGen Co., Ltd.

Recruiting

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

HER2 | Non-Muscle Invasive Bladder Cancer

China
White River Junction Veterans Affairs Medical Center
Medical University of South Carolina; National Cancer Institute (NCI); University...

Recruiting

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance (ReplaceCysto)

Non-muscle-invasive Bladder Cancer

United States
Al-Azhar University

Recruiting

Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

Non-muscle-invasive Bladder Cancer

Egypt
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)

Non-muscle-invasive Bladder Cancer

United States
VA Office of Research and Development
University of California, Davis

Recruiting

A Phase I Intravesical PPM Therapy for NMIBC

Non-muscle-invasive Bladder Cancer

United States
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR)

Recruiting

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (BicaBCa)

Non-Muscle Invasive Bladder Cancer

Canada
Clinical Hospital Centre Zagreb

Active, not recruiting

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

Croatia
Archivel Farma S.L.
Fundació Institut Germans Trias i Pujol

Completed

Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI® (RUTIVAC-1)

High-Risk Non-Muscle-Invasive Bladder Cancer

Spain
Omar Mian
Gilead Sciences; Varian Inc

Not yet recruiting

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder Carcinoma | Localized Muscle Invasive Bladder Urothelial Carcinoma

United States
Ractigen Therapeutics.

Recruiting

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Australia
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

Non-Muscle Invasive Bladder Cancer

United States, Israel
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

High-risk Non-muscle Invasive Bladder Cancer

China
Johns Hopkins University

Recruiting

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

Non-Muscle Invasive Bladder Cancer

United States
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

China

Clinical Trials on Non-Muscle Invasive Bladder Urothelial Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations